Last updated: October 31, 2026
REOPRO, the brand name for abciximab, is a platelet glycoprotein IIb/IIIa inhibitor developed for use during percutaneous coronary intervention. Its commercial position has deteriorated sharply since the 1990s because of reduced use of intravenous platelet inhibitors, competition from eptifibatide and tirofiban, changes in PCI practice, and the absence of a durable patent or regulatory moat. ReoPro remains a specialized hospital product rather than a broad commercial growth asset.
Public filings do not provide a current, standalone revenue series for ReoPro. Historical disclosures indicate that the product was commercially meaningful during the peak expansion of coronary angioplasty, but later financial reports grouped it within broader cardiovascular or hospital-product categories. Current value is tied to limited procedural use, supply continuity, and institutional protocols rather than market expansion.
What is REOPRO and how does abciximab work?
ReoPro is abciximab, a chimeric monoclonal antibody Fab fragment that binds platelet glycoprotein IIb/IIIa receptors and blocks fibrinogen-mediated platelet aggregation. It also binds vitronectin receptors involved in platelet activation and vascular-cell interactions.
The U.S. Food and Drug Administration approved ReoPro in 1994 for use in patients undergoing percutaneous transluminal coronary angioplasty and related coronary interventions. The product was initially positioned as an adjunct to reduce ischemic complications associated with coronary procedures.[1]
| Product attribute |
ReoPro |
| Active ingredient |
Abciximab |
| Drug class |
Glycoprotein IIb/IIIa platelet inhibitor |
| Dosage form |
Intravenous bolus followed by continuous infusion |
| Primary setting |
Hospital-based PCI |
| Original developer |
Centocor |
| Commercial history |
Later associated with Eli Lilly and other distribution arrangements |
| FDA pathway |
Legacy biologic approved before the modern BLA framework |
| Principal substitutes |
Eptifibatide, tirofiban, cangrelor, intensified oral antiplatelet therapy |
Unlike chronic cardiovascular drugs, ReoPro is administered around a procedure. Its market therefore depends on PCI volume, cath-lab protocols, bleeding-risk management, and the share of high-risk interventions requiring rapid platelet inhibition.
When did REOPRO lose commercial exclusivity?
ReoPro’s principal commercial exclusivity has expired. The product was approved in 1994, and any core composition or use patents associated with the original product would have expired no later than the late 2000s or early 2010s, depending on the patent family and applicable patent-term adjustments.
The product no longer has the characteristics of a protected, high-margin biologic franchise. Its remaining commercial defenses are practical rather than legal:
- Manufacturing complexity for a recombinant antibody fragment.
- Hospital familiarity and historical clinical experience.
- Procurement relationships.
- Regulatory burden associated with sterile injectable biologics.
- Limited expected return for a new entrant in a declining procedural market.
The FDA’s Orange Book and biologics records should be distinguished. ReoPro was approved under a legacy drug application framework, while modern biologics are generally licensed under BLAs. Publicly available FDA records do not indicate a current, commercially significant Orange Book patent barrier supporting a new period of exclusivity for abciximab.[2]
What is the FDA and regulatory status of REOPRO?
ReoPro was approved for adjunctive use during coronary intervention. The labeled product requires weight-based dosing and intravenous administration, with a bolus followed by infusion. Its principal safety concern is bleeding, including serious or life-threatening hemorrhage and thrombocytopenia.[1]
The regulatory profile has several commercial consequences:
- ReoPro requires hospital administration and monitoring.
- Its use is concentrated in cardiology procedural settings.
- Safety management increases pharmacy and cath-lab complexity.
- Newer protocols often favor alternative agents or reserve glycoprotein IIb/IIIa inhibitors for bailout use.
The product is listed in standard drug information systems, but listing does not establish strong current commercial demand. DailyMed identifies abciximab injection labeling and preserves the product’s approved prescribing information.[3]
Does REOPRO have FDA exclusivity?
No meaningful period of new-market exclusivity remains for ReoPro. Its original approval-era exclusivity has expired. The product does not benefit from orphan-drug exclusivity, pediatric exclusivity, or a recent supplemental approval that would materially extend market protection.
How large is the current market for abciximab?
The addressable market has contracted from its historical peak. ReoPro entered when glycoprotein IIb/IIIa inhibitors were used broadly in PCI. Current practice is more selective because of bleeding concerns, improved stenting technology, dual antiplatelet therapy, radial access, and the availability of alternative antiplatelet agents.
The commercial market now consists mainly of:
- High-risk PCI.
- Bailout treatment for thrombotic complications.
- Cases involving large thrombus burden.
- Institutions with established abciximab protocols.
- Regions where alternative agents are unavailable, expensive, or less familiar.
U.S. utilization is particularly constrained. Abciximab is less prominent in contemporary U.S. PCI practice than it was before the widespread adoption of newer antiplatelet strategies. Demand can remain more durable in selected international markets, especially where hospital formularies favor established injectable agents.
How does REOPRO compare with eptifibatide and tirofiban?
Eptifibatide and tirofiban are the closest pharmacologic competitors. Both are small-molecule glycoprotein IIb/IIIa inhibitors and generally have shorter pharmacologic effects than abciximab. That distinction can influence use when clinicians prioritize rapid reversibility or predictable clearance.
| Factor |
Abciximab |
Eptifibatide |
Tirofiban |
| Molecule type |
Antibody Fab fragment |
Cyclic heptapeptide |
Nonpeptide small molecule |
| Administration |
IV bolus and infusion |
IV bolus and infusion |
IV bolus and infusion |
| Receptor target |
GP IIb/IIIa and vitronectin-related binding |
GP IIb/IIIa |
GP IIb/IIIa |
| Pharmacologic profile |
Longer platelet-bound effect |
Shorter, reversible effect |
Shorter, reversible effect |
| Main commercial issue |
Aging product and limited use |
Generic and hospital-protocol competition |
Generic and hospital-protocol competition |
| Current strategic role |
Selective or bailout PCI use |
Selective PCI use |
Selective PCI use |
Cangrelor is another competitor in the broader procedural antiplatelet market. It is an intravenous P2Y12 inhibitor with rapid onset and offset. Oral P2Y12 inhibitors, including clopidogrel, prasugrel, and ticagrelor, also reduce the need for routine use of glycoprotein IIb/IIIa inhibitors.
What is the financial trajectory of REOPRO?
ReoPro’s financial trajectory has four stages.
1990s growth
ReoPro benefited from the rapid expansion of coronary angioplasty and the adoption of platelet inhibition as an adjunct to PCI. It was one of the more commercially important products in the early glycoprotein IIb/IIIa class.
At that time, the product had several favorable characteristics:
- A differentiated biologic mechanism.
- Strong procedural demand.
- High clinical visibility.
- Limited initial competition.
- Use in a rapidly expanding intervention category.
Early- to mid-2000s maturity
The market matured as eptifibatide and tirofiban gained adoption. Hospitals increasingly evaluated products through cost, bleeding risk, dosing convenience, and cath-lab protocols. The product remained commercially relevant but faced declining relative share.
Late-2000s to 2010s erosion
ReoPro’s financial contribution declined as PCI practice changed. Generic or lower-cost alternatives pressured pricing. Clinical studies and treatment guidelines increasingly supported selective rather than routine use of glycoprotein IIb/IIIa inhibitors.[4]
The product also lost the benefit of a protected-brand pricing model. Once patent protection and exclusivity ceased to constrain competition, hospital purchasing organizations gained leverage.
2020s niche positioning
Recent public company reports do not isolate ReoPro revenue in a way that supports a reliable current sales estimate. The product’s commercial profile is consistent with a mature, low-growth hospital injectable: limited volumes, procurement-driven pricing, regional availability differences, and low promotional intensity.
The product’s economics are likely more sensitive to manufacturing and distribution costs than to brand marketing. A disruption in sterile manufacturing could materially affect availability even when underlying demand is modest.
Are there generic or biosimilar challenges to REOPRO?
No major U.S. biosimilar competition has materially reshaped the ReoPro market. That outcome reflects the small and declining market, the complexity of developing and validating an antibody Fab product, and limited commercial incentives.
A potential competitor could enter through a biologics pathway or another abbreviated regulatory route, depending on the legal status of the reference product and FDA requirements. The main barriers would include:
- Cell-line and upstream manufacturing development.
- Control of aggregation and fragmentation.
- Potency and receptor-binding comparability.
- Sterile injectable production.
- Clinical and analytical bridging requirements.
- Hospital contracting and limited market size.
The absence of a major biosimilar does not imply strong patent protection. It reflects weak return on investment relative to development and regulatory costs.
Which companies compete with or challenge the REOPRO franchise?
The principal competitive pressure comes from manufacturers of alternative antiplatelet therapies rather than from a single direct ReoPro challenger.
Relevant competitors include:
- Manufacturers of generic eptifibatide.
- Manufacturers of generic tirofiban.
- The manufacturer of cangrelor.
- Suppliers of oral P2Y12 inhibitors.
- Hospital systems using procedural anticoagulation and antiplatelet protocols that avoid routine GP IIb/IIIa therapy.
ReoPro’s competitive position is therefore determined by therapeutic substitution. A hospital can reduce ReoPro use without adopting a direct abciximab competitor.
What patent litigation and settlement agreements affect REOPRO?
No major current U.S. patent litigation or settlement agreement appears to drive the commercial outlook for ReoPro. The important legal event is the historical expiration of core patent protection and the resulting shift from exclusivity-driven pricing to procurement-driven economics.
The main legal risks are now operational:
- Product liability claims involving bleeding or thrombocytopenia.
- Manufacturing and quality disputes.
- Distribution interruptions.
- Regulatory enforcement tied to injectable-product quality.
- Contract disputes involving hospital supply.
There is no current Paragraph IV campaign comparable to those affecting large chronic-use drugs. A Paragraph IV challenge would have limited commercial value because the original product’s principal exclusivity has already expired and the market is relatively small.
What manufacturing and intellectual-property barriers protect abciximab?
The strongest barriers are technical, not patent-based. Abciximab is a biologic Fab fragment requiring controlled production, purification, formulation, and sterile filling. Product quality depends on maintaining consistent binding activity and controlling impurities, aggregates, and degradation products.
These requirements can discourage entry, but they do not support premium pricing indefinitely. If demand falls below an efficient production scale, supply economics can become more important than market share.
Geographic protection is also limited. Patent expiry has removed the principal territorial barrier in major markets. Commercial access now depends on national approvals, local procurement, manufacturing registration, and distributor coverage.
What generic launch scenarios exist for REOPRO?
Three scenarios are commercially plausible.
Continued niche supply
ReoPro remains available for selected PCI cases and bailout use. The brand retains value through physician familiarity and established hospital protocols.
Regional substitution
Generic eptifibatide or tirofiban displaces abciximab in markets where price is the main procurement factor. This is the most likely ongoing pressure.
Supply-driven withdrawal
If manufacturing, quality, or distribution costs exceed the product’s contribution margin, the supplier could reduce geographic coverage or discontinue the product. A withdrawal would create a clinical supply issue but not necessarily a large commercial opportunity for a replacement producer.
How strong is the REOPRO patent estate?
The patent estate is commercially weak. Core product protection has expired, and no active patent position appears to create a meaningful barrier to alternative abciximab development. The remaining defensibility is based on manufacturing know-how, regulatory history, supply reliability, and customer relationships.
For investors or potential licensees, the product should be evaluated as a mature hospital injectable with limited upside, not as an actively protected biologic franchise.
What is the revenue exposure for the manufacturer?
Public financial statements do not provide a dependable current standalone revenue figure for ReoPro. The product’s revenue exposure is likely immaterial relative to the diversified pharmaceutical portfolios of its historical commercial sponsors.
The relevant financial variables are:
- Declining procedure-driven demand.
- Low growth in routine use.
- Price pressure from substitutes.
- Manufacturing overhead.
- Regional supply costs.
- Inventory and quality-control requirements.
- Potential liability and discontinuation costs.
ReoPro can generate positive contribution margin in a stable supply environment, but it is unlikely to influence the valuation of a large diversified pharmaceutical company.
Key Takeaways
- ReoPro is abciximab, an intravenous GP IIb/IIIa platelet inhibitor approved by the FDA in 1994.
- Its original commercial opportunity was tied to the rapid expansion of PCI.
- Routine use has declined because of bleeding concerns, procedural changes, oral antiplatelet therapy, and competing agents.
- Core patent and regulatory exclusivity have expired.
- No major current Paragraph IV campaign, biosimilar challenge, or patent litigation drives the market.
- Eptifibatide, tirofiban, cangrelor, and oral P2Y12 inhibitors are the principal substitutes.
- Current demand is concentrated in high-risk or bailout PCI and selected international markets.
- Public filings do not provide a reliable current standalone ReoPro revenue figure.
- Manufacturing complexity may limit entry, but it does not create a durable high-value patent moat.
- The principal commercial risk is continued substitution or supply withdrawal, not a sudden patent cliff.
FAQs
Is ReoPro still used in cardiac catheterization laboratories?
Yes. Use is concentrated in selected high-risk PCI and bailout situations rather than routine administration across all coronary interventions.
Is abciximab available as a generic drug?
The absence of a major U.S. generic or biosimilar competitor does not reflect active core patent protection. Development economics and the small market are more important barriers.
Does ReoPro have a biosimilar?
No commercially significant U.S. abciximab biosimilar has reshaped the market. The product’s biologic manufacturing requirements and limited demand reduce the incentive for development.
Which drug replaced ReoPro in most PCI procedures?
There is no single replacement. Eptifibatide, tirofiban, cangrelor, and oral P2Y12 inhibitors have collectively reduced abciximab use, while many patients receive no routine GP IIb/IIIa inhibitor.
Is ReoPro a growth opportunity for pharmaceutical investors?
Generally no. ReoPro is a mature, declining hospital product with limited exclusivity, narrow procedural demand, and substantial substitution risk. Its value is primarily tied to reliable supply and positive contribution margin.
References
-
U.S. Food and Drug Administration. (1994). ReoPro (abciximab) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
National Library of Medicine. (2024). DailyMed: Abciximab injection prescribing information. U.S. National Library of Medicine.
-
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., Khot, U. N., Lange, R. A., Mauri, L., Mehran, R., Moussa, I. D., Mukherjee, D., Nallamothu, B. K., & Ting, H. H. (2011). 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Journal of the American College of Cardiology, 58(24), e44-e122.
-
Eli Lilly and Company. (Various years). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission.
